The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
Satsuma Pharmaceuticals Q2 EPS $(0.38) Up From $(0.65) YoY
Satsuma Pharmaceuticals (NASDAQ:STSA) reported quarterly losses of $(0.38) per share. This is a 41.54 percent increase over losses of $(0.65) per share from the same period last year.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap stands at $87.4 million.
Mizuho Upgrades Satsuma Pharmaceuticals to Buy, Raises Price Target to $15
Mizuho analyst Vamil Divan upgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Neutral to Buy and raises the price target from $7 to $15.
21 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 29.2% to $3.71 in pre-market trading as traders circulated an article titled "Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst."
28 Stocks Moving in Friday’s Pre-Market Session
Gainers
CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.